Imatinib Viatris

Imatinib, the active ingredient in Imatinib Viatris, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats specific blood cancers and gastrointestinal stromal tumors in adult patients.

GNH USA supplies Imatinib Viatris as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib targets abnormal tyrosine‑kinase signaling in several malignancies, providing disease control in the following approved indications:

- Chronic myeloid leukemia (CML): achieves cytogenetic and molecular remission by inhibiting BCR‑ABL. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): supports remission induction and maintenance. - Gastrointestinal stromal tumor (GIST): reduces tumor growth driven by c‑KIT/PDGFR mutations. - Other BCR‑ABL positive neoplasms: provides targeted therapy where BCR‑ABL is a driver.

Adverse reactions vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Edema, especially peripheral - Muscle cramps or pain - Fatigue or weakness - Diarrhoea - Skin rash or pruritus

Serious or Rare Side Effects: - Hepatotoxicity (elevated transaminases, hepatitis) - Severe neutropenia or thrombocytopenia - Cardiac failure or reduced left‑ventricular function - Pulmonary arterial hypertension - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Life‑threatening haemorrhage

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly.

- Blood counts: monitor complete blood count weekly during early treatment. - Liver function: check transaminases and bilirubin before start and periodically. - Cardiac assessment: evaluate ejection fraction in patients with cardiac risk. - Drug interactions: avoid concomitant strong CYP3A4 inhibitors or inducers. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Store below 25°C: keep in the original pack, protect from moisture.

Imatinib may interact with several co‑administered medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may increase plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) – may reduce efficacy. - QT‑prolonging agents (e.g., sotalol, quinidine) – risk of arrhythmia. - Anticoagulants (e.g., warfarin) – may enhance anticoagulant effect.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors – may modestly affect absorption. - Diuretics – monitor electrolytes and renal function. - Oral contraceptives – reduced hormonal efficacy possible. - NSAIDs – increased risk of gastrointestinal bleeding. - Antihypertensives – watch for additive hypotensive effects.